INVO Bioscience, Inc. Receives 510(K) FDA Clearance for Expanded Use of the Invocell Device

INVO Bioscience, Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period. The data supporting the expanded 5-day incubation clearance demonstrated improved patient outcomes.